Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-102370
Filing Date
2024-11-26
Accepted
2024-11-25 21:34:37
Documents
47
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0221502-10q_abprohold.htm   iXBRL 10-Q 749655
2 CERTIFICATION ea022150201ex31-1_abprohold.htm EX-31.1 11765
3 CERTIFICATION ea022150201ex31-2_abprohold.htm EX-31.2 11363
4 CERTIFICATION ea022150201ex32-1_abprohold.htm EX-32.1 4538
5 CERTIFICATION ea022150201ex32-2_abprohold.htm EX-32.2 4363
  Complete submission text file 0001213900-24-102370.txt   5695233

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE acab-20240930.xsd EX-101.SCH 53692
7 XBRL CALCULATION FILE acab-20240930_cal.xml EX-101.CAL 21246
8 XBRL DEFINITION FILE acab-20240930_def.xml EX-101.DEF 287433
9 XBRL LABEL FILE acab-20240930_lab.xml EX-101.LAB 468019
10 XBRL PRESENTATION FILE acab-20240930_pre.xml EX-101.PRE 279597
50 EXTRACTED XBRL INSTANCE DOCUMENT ea0221502-10q_abprohold_htm.xml XML 560936
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41224 | Film No.: 241497913
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)